Leerink Partnrs upgraded shares of Tectonic Therapeutic (NASDAQ:TECX – Free Report) to a strong-buy rating in a research report report published on Wednesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Tectonic Therapeutic’s Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($3.49) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($2.62) EPS, FY2027 earnings at ($3.82) EPS and FY2028 earnings at ($3.99) EPS.
Other equities analysts have also recently issued reports about the company. TD Cowen began coverage on Tectonic Therapeutic in a report on Monday, June 24th. They issued a buy rating on the stock. SVB Leerink started coverage on shares of Tectonic Therapeutic in a research report on Wednesday. They issued an outperform rating and a $49.00 price target on the stock. Finally, Piper Sandler assumed coverage on Tectonic Therapeutic in a report on Wednesday, June 26th. They set an overweight rating and a $76.00 price objective for the company.
Check Out Our Latest Stock Analysis on Tectonic Therapeutic
Tectonic Therapeutic Stock Performance
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. On average, analysts forecast that Tectonic Therapeutic will post -4.24 earnings per share for the current fiscal year.
Tectonic Therapeutic Company Profile
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
Read More
- Five stocks we like better than Tectonic Therapeutic
- What Are Dividend Contenders? Investing in Dividend Contenders
- Why Call Options Volume for These 2 Stocks Spiked Together
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 7/22 – 7/26
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.